HERON THERAPEUTICS, INC. /DE/ 4
4 · HERON THERAPEUTICS, INC. /DE/ · Filed Oct 13, 2015
Insider Transaction Report
Form 4
Clendeninn Neil James
SVP & Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2015-10-12+50,000→ 50,000 totalExercise: $28.30Exp: 2025-10-12→ Common Stock (50,000 underlying) - Award
Stock Option (Right to Buy)
2015-10-12+100,000→ 100,000 totalExercise: $28.30Exp: 2025-10-12→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]Options shall vest and become exercisable with respect to 25,000 shares on the first anniversary of his first day of employment (the "Grant Date"), followed by 75,000 shares vesting ratably each month over the subsequent three years, such that 100,000 options will be fully vested on the four year anniversary of the Grant Date.
- [F2]Option shall vest and become exercisable in full upon approval of SUSTOL (granisetron) Injection, extended release by the U.S. Food and Drug Administration.